KR20100020981A - 암 치료를 위한 ｃｈｋ 및 ｐａｒｐ 억제제의 조합물 - Google Patents

암 치료를 위한 ｃｈｋ 및 ｐａｒｐ 억제제의 조합물 Download PDF

Info

Publication number
KR20100020981A
KR20100020981A KR1020097026995A KR20097026995A KR20100020981A KR 20100020981 A KR20100020981 A KR 20100020981A KR 1020097026995 A KR1020097026995 A KR 1020097026995A KR 20097026995 A KR20097026995 A KR 20097026995A KR 20100020981 A KR20100020981 A KR 20100020981A
Authority
KR
South Korea
Prior art keywords
alkyl
cancer
heterocyclyl
aryl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097026995A
Other languages
English (en)
Korean (ko)
Inventor
마크 제임스 오'코너
그레임 카메론 머레이 스미스
소냐 자블루도프
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20100020981A publication Critical patent/KR20100020981A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097026995A 2007-05-25 2008-05-23 암 치료를 위한 ｃｈｋ 및 ｐａｒｐ 억제제의 조합물 Withdrawn KR20100020981A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
US60/940,203 2007-05-25

Publications (1)

Publication Number Publication Date
KR20100020981A true KR20100020981A (ko) 2010-02-23

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097026995A Withdrawn KR20100020981A (ko) 2007-05-25 2008-05-23 암 치료를 위한 ｃｈｋ 및 ｐａｒｐ 억제제의 조합물

Country Status (11)

Country Link
US (1) US20100249112A1 (https=)
EP (1) EP2167086A1 (https=)
JP (1) JP2010527981A (https=)
KR (1) KR20100020981A (https=)
CN (1) CN101743003A (https=)
AU (1) AU2008256562A1 (https=)
BR (1) BRPI0811059A2 (https=)
CA (1) CA2687786A1 (https=)
MX (1) MX2009012705A (https=)
RU (1) RU2009147819A (https=)
WO (1) WO2008146035A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP7273791B2 (ja) 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2019194738A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
ATE501138T1 (de) * 2004-01-05 2011-03-15 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
US20060204981A1 (en) * 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Also Published As

Publication number Publication date
WO2008146035A1 (en) 2008-12-04
BRPI0811059A2 (pt) 2017-05-09
CN101743003A (zh) 2010-06-16
CA2687786A1 (en) 2008-12-04
AU2008256562A1 (en) 2008-12-04
US20100249112A1 (en) 2010-09-30
EP2167086A1 (en) 2010-03-31
RU2009147819A (ru) 2011-06-27
JP2010527981A (ja) 2010-08-19
MX2009012705A (es) 2009-12-08

Similar Documents

Publication Publication Date Title
KR20100020981A (ko) 암 치료를 위한 ｃｈｋ 및 ｐａｒｐ 억제제의 조합물
AU2004220321B2 (en) Phthalazinone derivatives
KR102753101B1 (ko) 약제학적 화합물
JP2009512671A (ja) ４−ヘテロアリールメチル置換されたフタラジノン誘導体
BR112013013435B1 (pt) composto, composição farmacêutica, uso de um composto,e, processo para a preparação de um composto
KR20070057859A (ko) 4-헤테로아릴메틸 치환된 프탈라지논 유도체
CA2691459A1 (en) Phthalazinone derivatives as inhibitors of parp-1
NZ585982A (en) Phthalazinone derivatives for ibhibiting the activity of the enzyme poly (ADP-ribose)polymerase-1 (PARP-1)
HUE029275T2 (en) Phthalazinone ketone derivative, method of preparation and therapeutic use
KR20100016366A (ko) 프탈라지논 유도체 및 암 치료를 위한 약제로서의 이의 용도
WO2008114023A2 (en) Phthalazinone derivatives
KR20050119647A (ko) 신규한 융합 트리아졸론 및 이의 용도
CA3135070A1 (en) Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
CA2699038A1 (en) Phthalazinone derivatives
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
BRPI0111743B1 (pt) Composições farmacêuticas compreendendo um enantiômero de quinolina 1,2-anelada que inibe farnesil transferase e seu processo de preparação
US12404244B2 (en) Pan-KIT kinase inhibitor having quinoline structure and application thereof
EP3878841A1 (en) Indazole kinase inhibitor and use thereof
HK40052071B (en) Pan-kit kinase inhibitor having quinoline structure and application thereof
HK1187916B (en) Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
MX2008004913A (en) 4-heteroarymethyl substituted phthalazinone derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid